The clinical utility of the detection of TKI sensitizing EGFR mutations in ctDNA has been proven when treating patients with gefitinib[3] in NSCLC and with erlotinib in colorectal cancer (CRC)[10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.